New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:09 EDTRTRXRetrophin raises FY14 revenue view to $19M-$21M from $10M-$12M
One estimate $11M. Raises FY15 revenue view to $35M-$40M from $19M-$21M, one estimate $20M. Retrophin CEO Martin Shkreli said, “Reimbursement of Chenodal has remained robust, and initial efforts to find undiagnosed cerebrotendinous xanthomatosis patients are promising. We have raised our guidance for 2014 and 2015 revenue accordingly. We are very comfortable with our current cash balance and future obligations. The success of Chenodal significantly reduces our cash needs and may propel the company to profitability in the near-term. As such, we have no need or desire to explore a dilutive equity offering unless it is accompanied by an accretive and strategic acquisition. Retrophin remains opportunistic with respect to M&A and has strong access to both debt and equity capital.”
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
07:11 EDTRTRXLeerink to hold a roundtable
Subscribe for More Information
September 23, 2015
06:29 EDTRTRXOrphan drug pricing concerns overdone, says Leerink
Leerink analyst Joseph Schwartz says his firm's Orphan Drug Payor survey contrasts with the recent bearish investor sentiment over the orphan drug business model. The survey of 30 payors indicates that the reimbursement landscape "remains highly favorable" for commercially insured patients and is able to withstand potential weakness caused by proposed changes to Medicare pricing, Schwartz tells investors in a research note. His analysis suggests a "surprisingly limited" impact to valuations of orphan drug companies should Medicare patients receive drug discounts. Schwartz views the pricing concerns stemming from Hillary Clinton's plan to combat high drug prices as overdone. He reiterates Outperform ratings on AMAG Pharmaceuticals (AMAG), BioMarin (BMRN), Raptor Pharmaceuticals (RPTP) and Retrophin (RTRX).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use